Patent: 5,108,909
✉ Email this page to a colleague
▶ Start for $100
Remove trial restrictions
Summary for Patent: 5,108,909
Title: | Expression of TPA in mammalian cells |
Abstract: | Improved expression of tPA in mammalian cells is achieved employing a promoter region functional in a mammalian cell with a DNA sequence coding for tPA, where the sequence is interrupted by at least one intron. Particularly, a viral promoter is employed in conjunction with a hybrid gene having portions of the coding sequence uninterrupted by introns as compared to the wild-type gene and coding sequences interrupted by introns or the wild-type gene or mutants thereof. Plasmid pSV7tPA2I was deposited on Feb. 14, 1985 and given A.T.C.C. Accession No. 40163. |
Inventor(s): | Haigwood; Nancy L. (Oakland, CA) |
Assignee: | Chiron Corporation (Emeryville, CA) |
Application Number: | 07/097,271 |
Patent Claims: | see list of patent claims |
Details for Patent 5,108,909
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Sign Up | 2009-04-28 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Sign Up | 2009-04-28 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Sign Up | 2009-04-28 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |